Loganetin protects against rhabdomyolysis-induced acute kidney injury by modulating the toll-like receptor 4 signalling pathway.

Jie LiYu-Jun TanMing-Zhi WangYing SunGuang-Yan LiQi-Long WangJing-Chun YaoJiang YueZhong LiuGui-Min ZhangYu-Shan Ren

Published in: British journal of pharmacology (2019)

All the results suggested that TLR4 plays a critical role in AKI development, and Loganetin ameliorates AKI by inhibiting TLR4 activity and blocking the JNK/p38 pathway, which provides a new strategy for AKI treatment.

Keyphrases

toll like receptor
acute kidney injury
signaling pathway
inflammatory response
nuclear factor
immune response
cell death
induced apoptosis
oxidative stress
replacement therapy